Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott Laboratories ABT is scheduled to release its financial results for the second quarter, before the opening bell on Thursday, July 18.

Abbott Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Abbott (NYSE: ABT) will report its Q2 2024 results on Thursday, July 18. We expect the company to post revenue of $10.3 billion and earnings of $1.10 on a per share and adjusted basis, broadly aligning with the street expectations.

Down 7% This Year Will Abbott Stock See Higher Levels Post Q2 Results?

Gilead Sciences

HCA Healthcare

Medtronic

Novartis

Pfizer

Tenet Healthcare

Over the years, especially the past three, I have become more cautious about the technology sector's blatant overvaluation. Nevertheless, it is difficult to ignore the capabilities of companies such as Nvidia (NASDAQ: NVDA ) and their innovative solutions for AI.

The 7 Most Undervalued Healthcare Stocks to Buy in July 2024

Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.

Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release

AstraZeneca

Intuitive Surgical

Merck

PACS Group, Inc.

In my view, it's important for every individual to invest in equities. By just holding cash in a back account, there is bound to be loss of purchasing power when adjusted for inflation.

7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns

In the latest trading session, Abbott (ABT) closed at $101.64, marking a -0.47% move from the previous day.

Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note

Similac baby formula maker Abbott is expected to face a trial on Monday over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease, the second trial out of hundreds of similar lawsuits in the United States.

Abbott trial on preterm infant formula linked to NEC disease kicks off this week

Abbott faces trial over claims that preterm infant formula caused dangerous disease

The S&P 500 gained 2% last week despite weak employment data and manufacturing sentiment, driven by optimism about potential Fed rate cuts. Abbott Laboratories, though lagging the S&P 500, shows promise with diversified growth in diagnostics, nutrition, diabetes care, and heart health. With a strong dividend and innovation-driven outlook, Abbott is well-positioned for long-term gains, although current high valuations suggest cautious optimism.

Abbott Laboratories: The Fantastic Mix Of Growth And Value - At A Great Price

Amgen

Eli Lilly

The COVID-19 pandemic emphasized the importance of healthcare companies. Consistent breakthroughs, improved products and relatively consistent growth make these companies fan-favorite picks for investors.

The 3 Best Healthcare Stocks to Buy in July 2024

Albemarle

Franklin Resources

C.H. Robinson Worldwide

Clorox

Hormel Foods

McCormick

Nordson

ProShares S&P 500 Dividend Aristocrats ETF

Realty Income Corp

SPDR S&P 500 ETF Trust

Stanley Black & Decker

Target

The ProShares S&P 500 Dividend Aristocrats ETF continues its positive run in 2024, posting a gain of 1.45% in May. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 35 months of tracking these strategies, two strategies are outperforming NOBL, while 1 remain relatively close.

My Best Dividend Aristocrats For July 2024

Abbott stock (NYSE: ABT) currently trades at $105 per share, 25% below its peak level of over $140 seen in December 2021. In comparison, its peer Boston Scientific stock (NYSE: BSX) has seen a nearly 90% rise over this period.

How Does The Current Fall In Abbott Stock Compare With The One During 2008 Recession?

Inmode Ltd

Outset Medical

Fundamentally, few sectors exist outside of the broad healthcare umbrella that offer what I would term permanent relevance. In this case, the concept of caring for other people is likely an eternal one.

3 MedTech Stocks to Buy for Healthy Gains

ConocoPhillips

Cisco Systems

The June/July 2024 edition of Fortune Magazine revealed the 500 biggest U.S. companies by-revenue and profits. Dogcatcher's quest for dividend buys focused-on 66 industry-eaders (IL) using YCharts 6/26/24 data. Those 66 industry-leaders were segmented into 21 business-sectors, ranging (alphabetically) from apparel to wholesalers. 3 of 66 were private or foreign exchange-listed firms not tracked-by YChats, leaving 63-listed. 57 dividend yielding stocks led those 63 industry leaders and ranged 0.03% to 8.46% in annual yield and ranged -13.69% to 47.15% in broker estimated one-year target-price upsides.

Buy 3 June Fortune 500 Industry Dividend Leaders (Watch 4 More)

ABBOTT PARK, Ill., June 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens.

Abbott Hosts Conference Call for Second-Quarter Earnings

In the closing of the recent trading day, Abbott (ABT) stood at $105.49, denoting a +0.18% change from the preceding trading day.

Abbott (ABT) Exceeds Market Returns: Some Facts to Consider

Banking on the successful execution of its Branded Generic operating model, Abbott's (ABT) EPD is well-positioned for sustained growth in many of the growing pharmaceutical markets.

Abbott's (ABT) EPD Expansion Continues Despite FX Headwind

Eight health centers across the U.S. participate in Innovation Incubator to find new ways to integrate healthy food into clinical care Now in its second year, the goal of the Innovation Incubator is to share what works with 1,400 health centers providing affordable care for 31+ million ABBOTT PARK, Ill. and BETHESDA, Md.

Abbott Teams Up With the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

Abbott (ABT) concluded the recent trading session at $103.45, signifying a -0.22% move from its prior day's close.

Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade

Altimmune

DexCom

Regeneron Pharmaceuticals

Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.

New Weight-Loss Drugs and Devices Are Coming This Week

Huntington Ingalls Industries

Mondelez

The S&P 500 has seen impressive returns, largely driven by a few tech giants, raising concerns about diversification risks for investors. Investing in high-quality, anti-cyclical stocks can offer balanced growth and income, providing a safer alternative to the tech-heavy S&P 500. These selected stocks present attractive valuations and potential for long-term gains, making them solid choices for investors seeking growth and income stability.

Forget The S&P 500 - Here Are 3 Low-Risk, High-Quality Dividend Bargains I Like

ABBOTT PARK, Ill., June 14, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.

Abbott Declares 402nd Consecutive Quarterly Dividend

Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.

Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark

Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.

Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems

Vertex Pharmaceuticals

Vertex Pharmaceuticals and Abbott Laboratories are innovative healthcare leaders. Both companies have robust businesses and excellent potential opportunities.

News for Abbott Labs Stock (ABT)